CMG Pharmaceutical
CompanySouth Korea
CMG Pharmaceutical develops one asset, in phase 3 (CMG190303 in dyslipidemia). Mostly small molecule acting on lipid and ceramide metabolism, SLC5A2 and HMGCR; based in South Korea.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Fixed-dose combination of SGLT2 inhibitor dapagliflozin and HMG-CoA reductase inhibitor rosuvastatin
Phase 3, Small molecule, Lipid and ceramide metabolism, SLC5A2, dyslipidemia, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials1
- Similar companies6